PMID- 36619542 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20230127 IS - 1664-2392 (Print) IS - 1664-2392 (Electronic) IS - 1664-2392 (Linking) VI - 13 DP - 2022 TI - Potential role of 25(OH)D insufficiency in the dysfunction of glycolipid metabolism and cognitive impairment in patients with T2DM. PG - 1068199 LID - 10.3389/fendo.2022.1068199 [doi] LID - 1068199 AB - PURPOSE: To investigate the changes of plasma 25(OH)D levels in type 2 diabetes mellitus (T2DM) patients and explore its role in the dysfunction of glucose and lipid metabolism and cognition. METHODS: One hundred and thirty-two T2DM patients were enrolled and the demographic and clinical data were collected. The plasma concentration of 25(OH)D was detected and the patients were divided into two groups including a Vitamin D insufficient (VDI) group and a normal VD group according to the clinical diagnostic criterial of VDI with the plasma 25(OH)D level less than 29 ng/mL. The glycolipid metabolic and routine blood biochemical indices were detected, the plasma concentrations of C-reactive protein (CRP), interleukin-6 (IL-6), soluble myeloid soluble trigger receptor 1 (sTREM1) were measured. The cognitive function was assessed using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A). The depressive symptomatology was assessed using the Center for Epidemiological Survey Depression Scale (CES-D). Sleep quality was assessed using the Pittsburgh sleep quality index (PSQI). RESULTS: There were 70 T2DM patients with VDI (70/132, 53.03%) in this study. The plasma concentrations of glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial blood glucose (PBG), IL-6, and sTREM1 were remarkably increased in T2DM patients with VDI as compared with that with the normal VD, accompanied with an elevated BRIEF-A scores. There was no significant difference between groups with regard to the indices of blood lipid, liver function, and scores in CES-D and PSQI. Moreover, results of Pearson correlation test showed that the plasma 25(OH)D levels were negatively correlated with HbA1c, FPG, PBG, CRP, IL-6, sTREM1, CES-D sum scores, and PSQI sum scores, but positively correlated with the plasma levels of Serum creatinine (Scr). Furthermore, result of Receiver Operating Characteristic (ROC) curve analysis showed a predictive role of VDI levels in discriminating T2DM patients with higher cognitive impairments, with the sensitivity and specificity being 62.12% and 62.12%, respectively. CONCLUSION: VDI is harmful for T2DM patients with a significant relation with the hyperglycosemia and cognitive dysfunction. CI - Copyright (c) 2022 Sun, Yu, Gao, Wei, Qi, Ma, Xu, Xu and Ge. FAU - Sun, Hui-Min AU - Sun HM AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China. FAU - Yu, Yue AU - Yu Y AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - Department of Pharmacy, North district of The First Affiliated Hospital of Anhui Medical University, Hefei, China. FAU - Gao, Xin-Ran AU - Gao XR AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China. FAU - Wei, Ya-Dong AU - Wei YD AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China. FAU - Qi, Chuan-Zong AU - Qi CZ AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China. FAU - Ma, Meng-Die AU - Ma MD AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China. FAU - Xu, Dan-Dan AU - Xu DD AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China. FAU - Xu, Ya-Yun AU - Xu YY AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - School of Public Health, Anhui Medical University, Hefei, China. FAU - Ge, Jin-Fang AU - Ge JF AD - School of Pharmacy, Anhui Medical University, Hefei, China. AD - The Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei, China. AD - Anhui Provincial laboratory of inflammatory and immunity disease, Anhui Institute of Innovative Drugs, Hefei, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221223 PL - Switzerland TA - Front Endocrinol (Lausanne) JT - Frontiers in endocrinology JID - 101555782 RN - A288AR3C9H (25-hydroxyvitamin D) RN - 0 (Glycated Hemoglobin) RN - 0 (Interleukin-6) RN - 0 (Blood Glucose) RN - 0 (Glycolipids) SB - IM MH - Adult MH - Humans MH - *Diabetes Mellitus, Type 2/metabolism MH - Glycated Hemoglobin MH - Interleukin-6/metabolism MH - Blood Glucose/analysis MH - *Cognitive Dysfunction/complications MH - Lipid Metabolism MH - Glycolipids PMC - PMC9822724 OTO - NOTNLM OT - 25(OH)D OT - BRIEF-A OT - CRP OT - HbA1c OT - IL-6 OT - T2DM OT - sTREM1 COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/01/10 06:00 MHDA- 2023/01/11 06:00 PMCR- 2022/01/01 CRDT- 2023/01/09 03:53 PHST- 2022/10/12 00:00 [received] PHST- 2022/12/09 00:00 [accepted] PHST- 2023/01/09 03:53 [entrez] PHST- 2023/01/10 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fendo.2022.1068199 [doi] PST - epublish SO - Front Endocrinol (Lausanne). 2022 Dec 23;13:1068199. doi: 10.3389/fendo.2022.1068199. eCollection 2022.